Jingmin Yang1, Xiao Li1, Danyan Xu2. 1. Department of Cardiology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410000, Hunan, China. 2. Department of Cardiology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410000, Hunan, China. xudanyan02@csu.edu.cn.
Abstract
BACKGROUND: Multiple genetic studies have confirmed the definitive link among the loss-of-function variants of angiogenin-like protein 4 (ANGPTL4), significantly decreased plasma triglyceride (TG) levels, and reduced risk of coronary heart disease (CHD). The potential therapeutic effect of ANGPTL4 on dyslipidemia and CHD has been widely studied. OBJECTIVE: This review provides a detailed introduction to the research progress on the involvement of ANGPTL4 in lipid metabolism and atherosclerosis and evaluates the efficacy and safety of ANGPTL4 as a therapeutic target for CHD. RELEVANT FINDINGS: By inhibiting lipoprotein lipase (LPL) activity, ANGPTL4 plays a vital role in the regulation of lipid metabolism and energy balance. However, the role of ANGPTL4 in regulating lipid metabolism is tissue-specific. ANGPTL4 acts as a locally released LPL inhibitor in the heart, skeletal muscle and small intestine, while ANGPTL4 derived from liver and adipose tissue mainly acts as an endocrine factor that regulates systemic lipid metabolism. As a multifunctional protein, ANGPTL4 also inhibits the formation of foam cells in macrophages, exerting an anti-atherogenic role. The function of ANGPTL4 in endothelial cells is still uncertain. The safety of ANGPTL4 monoclonal antibodies requires further evaluation due to their potential adverse effects. CONCLUSION: The biological characteristics of ANGPTL4 are much more complex than those demonstrated by genetic studies. Future studies must elucidate how to effectively reduce the risk of CHD while avoiding potential atherogenic effects and other complications before the "prime time" of ANGPTL4-targeted therapy arrives.
BACKGROUND: Multiple genetic studies have confirmed the definitive link among the loss-of-function variants of angiogenin-like protein 4 (ANGPTL4), significantly decreased plasma triglyceride (TG) levels, and reduced risk of coronary heart disease (CHD). The potential therapeutic effect of ANGPTL4 on dyslipidemia and CHD has been widely studied. OBJECTIVE: This review provides a detailed introduction to the research progress on the involvement of ANGPTL4 in lipid metabolism and atherosclerosis and evaluates the efficacy and safety of ANGPTL4 as a therapeutic target for CHD. RELEVANT FINDINGS: By inhibiting lipoprotein lipase (LPL) activity, ANGPTL4 plays a vital role in the regulation of lipid metabolism and energy balance. However, the role of ANGPTL4 in regulating lipid metabolism is tissue-specific. ANGPTL4 acts as a locally released LPL inhibitor in the heart, skeletal muscle and small intestine, while ANGPTL4 derived from liver and adipose tissue mainly acts as an endocrine factor that regulates systemic lipid metabolism. As a multifunctional protein, ANGPTL4 also inhibits the formation of foam cells in macrophages, exerting an anti-atherogenic role. The function of ANGPTL4 in endothelial cells is still uncertain. The safety of ANGPTL4 monoclonal antibodies requires further evaluation due to their potential adverse effects. CONCLUSION: The biological characteristics of ANGPTL4 are much more complex than those demonstrated by genetic studies. Future studies must elucidate how to effectively reduce the risk of CHD while avoiding potential atherogenic effects and other complications before the "prime time" of ANGPTL4-targeted therapy arrives.
Entities:
Keywords:
Angiogenin-like protein 4 (ANGPTL4); Coronary heart disease (CHD); Lipid metabolism; Lipoprotein lipase (LPL); Loss-of-function variants; This work was supported by National Natural Scientific Funding of China (No. 81672264 and No. 81871858).
Authors: Paul S Jellinger; Donald A Smith; Adi E Mehta; Om Ganda; Yehuda Handelsman; Helena W Rodbard; Mark D Shepherd; John A Seibel Journal: Endocr Pract Date: 2012 Mar-Apr Impact factor: 3.443
Authors: Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano Journal: Atherosclerosis Date: 2016-09-01 Impact factor: 5.162
Authors: Mark J Graham; Richard G Lee; Teresa A Brandt; Li-Jung Tai; Wuxia Fu; Raechel Peralta; Rosie Yu; Eunju Hurh; Erika Paz; Bradley W McEvoy; Brenda F Baker; Nguyen C Pham; Andres Digenio; Steven G Hughes; Richard S Geary; Joseph L Witztum; Rosanne M Crooke; Sotirios Tsimikas Journal: N Engl J Med Date: 2017-05-24 Impact factor: 91.245
Authors: Frederick E Dewey; Viktoria Gusarova; Richard L Dunbar; Colm O'Dushlaine; Claudia Schurmann; Omri Gottesman; Shane McCarthy; Cristopher V Van Hout; Shannon Bruse; Hayes M Dansky; Joseph B Leader; Michael F Murray; Marylyn D Ritchie; H Lester Kirchner; Lukas Habegger; Alex Lopez; John Penn; An Zhao; Weiping Shao; Neil Stahl; Andrew J Murphy; Sara Hamon; Aurelie Bouzelmat; Rick Zhang; Brad Shumel; Robert Pordy; Daniel Gipe; Gary A Herman; Wayne H H Sheu; I-Te Lee; Kae-Woei Liang; Xiuqing Guo; Jerome I Rotter; Yii-Der I Chen; William E Kraus; Svati H Shah; Scott Damrauer; Aeron Small; Daniel J Rader; Anders Berg Wulff; Børge G Nordestgaard; Anne Tybjærg-Hansen; Anita M van den Hoek; Hans M G Princen; David H Ledbetter; David J Carey; John D Overton; Jeffrey G Reid; William J Sasiela; Poulabi Banerjee; Alan R Shuldiner; Ingrid B Borecki; Tanya M Teslovich; George D Yancopoulos; Scott J Mellis; Jesper Gromada; Aris Baras Journal: N Engl J Med Date: 2017-05-24 Impact factor: 91.245
Authors: Robert S Rosenson; Michael H Davidson; Benjamin J Hirsh; Sekar Kathiresan; Daniel Gaudet Journal: J Am Coll Cardiol Date: 2014-12-16 Impact factor: 24.094
Authors: François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund Journal: Eur Heart J Date: 2020-01-01 Impact factor: 29.983
Authors: Peter P Toth; Craig Granowitz; Michael Hull; Djibril Liassou; Amy Anderson; Sephy Philip Journal: J Am Heart Assoc Date: 2018-08-07 Impact factor: 5.501
Authors: Lihua Wang; Dan Western; Jigyasha Timsina; Charlie Repaci; Won-Min Song; Joanne Norton; Pat Kohlfeld; John Budde; Sharlee Climer; Omar H Butt; Daniel Jacobson; Michael Garvin; Alan R Templeton; Shawn Campagna; Jane O'Halloran; Rachel Presti; Charles W Goss; Philip A Mudd; Beau M Ances; Bin Zhang; Yun Ju Sung; Carlos Cruchaga Journal: medRxiv Date: 2022-07-25